Trial Profile
A Phase 2 Open-Label Study Evaluating the Efficacy and Safety of Telatinib in Combination with Chemotherapy as First-line Therapy in Subjects with Advanced Gastric Cancer
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 31 Mar 2015
Price :
$35
*
At a glance
- Drugs Telatinib (Primary) ; Capecitabine; Cisplatin
- Indications Gastric cancer
- Focus Therapeutic Use
- Sponsors ACT Biotech
- 31 Mar 2015 Status changed from completed to discontinued as per M.D. Anderson Cancer Center record.
- 07 Feb 2012 Actual end date (Jan 2012) added as reported by ClinicalTrials.gov.
- 07 Feb 2012 Actual patient number is 48 according to ClinicalTrials.gov.